Clinical Trial Update: EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults [Phase 1]

View source ↗

Summary

A Phase 1 trial update for EGFR806 CAR T cell immunotherapy in pediatric and young adult patients with recurrent/refractory solid tumors; the study is active bu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Desmoplastic Small Round Cell Tumor
• Ewing Sarcoma
• Hepatoblastoma
• Neuroblastoma
• Osteosarcoma
• Retinoblastoma
• Rhabdomyosarcoma
• Wilms Tumor

Drugs mentioned

• EGFR806 CAR T Cell Immunotherapy (EGFR806 CAR T)

Snippet

Sponsor: Seattle Children's Hospital | Conditions: Pediatric Solid Tumor, Germ Cell Tumor | Phase 1 | Status: ACTIVE_NOT_RECRUITING